Drugs / ONO-2020
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05507515 | Jul 2022 → Dec 2023 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06803823 | May 2025 → Dec 2026 expected | — | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06881836 | Apr 2025 → Jul 2026 overdue | Alzheimer disease | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507515 ↗ |
| Route | Oral | “Single ascending doses of ONO-2020 orally under fasted conditions” NCT05507515 ↗ |